RxDoctor Payments Data

Jane Lamp, MD

Family Medicine · Loxahatchee, FLNPI 1659366425

Payments from drug & device makers

$8,014in general payments, 2019–2025

Across 401 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • Bayer$632
  • Pfizer$538
  • AbbVie$463
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$7,96399%
  • Education$511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,014 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$242,448
Medicare patients
342
Services billed
2,996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$51,627
EliquisApixaban14$17,420
JardianceEmpagliflozin11$13,396
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$11,817
XareltoRivaroxaban11$11,480
MounjaroTirzepatide12$11,418
TrulicityDulaglutide15$11,164
FarxigaDapagliflozin Propanediol11$9,670
Tresiba Flextouch U-100Insulin Degludec15$9,139
Repatha SureclickEvolocumab15$8,279
SynthroidLevothyroxine Sodium29$2,729
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,650
Atorvastatin Calcium182$2,023
Levothyroxine Sodium136$1,642
Bupropion XlBupropion Hcl46$1,511

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,453$51,62743 claims
Lilly USA, LLCMounjaro, Trulicity$1,036$22,58227 claims
PfizerEliquis$538$17,42014 claims
Boehringer IngelheimJardiance$32$13,39611 claims
GSKTrelegy Ellipta$277$11,81713 claims
AstraZenecaFarxiga$1,663$9,67011 claims
AbbVieSynthroid$463$2,72929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Loxahatchee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →